How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, approximately half of patients experience 1 or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive agents. At progression, stan...
Main Authors: | De Carolis, L. (Author), Falini, B. (Author), Tiacci, E. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier B.V.
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
BRAF mutation in hairy cell leukemia
by: Ahmad Ahmadzadeh, et al.
Published: (2014-09-01) -
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
by: Tadeusz Robak, et al.
Published: (2021-06-01) -
Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors
by: Steve Biko Otieno, et al.
Published: (2020-01-01) -
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
by: Robert J. Kreitman, et al.
Published: (2021-02-01) -
How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)